INCPF Stock Chart & Stats
$1.55
--
Market closed
$1.55
--
Day’s Range― - ―
52-Week Range$1.55 - $3.26
Previous CloseN/A
VolumeN/A
Average Volume (3M)6.00
Market Cap
$2.82B
Enterprise Value$17.92K
Total Cash (Recent Filing)$7.07B
Total Debt (Recent Filing)$1.80B
Price to Earnings (P/E)32.6
Beta0.19
Next Earnings
Aug 24, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding1,496,284,200
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.46Price Target Upside58.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$265.36M
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained very high gross margin and healthy operating and net margins indicate durable product-level economics and pricing power from proprietary therapies. This margin profile supports reinvestment in R&D and commercialization without immediate reliance on external funding, strengthening long-term profitability.
Controlled Leverage And Capital BaseLow debt relative to equity and a sizable equity base reduce refinancing and solvency risk, giving management flexibility to fund trials, manufacturing or selective M&A. Controlled leverage improves resilience to biotech cash-cycle swings and supports consistent execution over the next several quarters.
Profitability Inflection And RecoveryA structural shift from prior losses to sustained profitability signals improved commercialization and cost discipline. This inflection reduces existential execution risk and, if maintained, provides a more predictable base to scale marketed products and fund continuing clinical programs over the medium term.
Bears Say
Weak And Volatile Cash ConversionProfitability has not consistently converted into cash, with a steep drop in free cash flow versus 2025. Persistent cash conversion weakness raises risk the company will need external financing for R&D or commercialization, reducing runway and increasing dilution or interest burden over time.
Inconsistent Revenue GrowthUneven top-line trends suggest commercial traction is fragile and new product sales may not yet be fully scalable. Continued inconsistent growth makes long-term planning for R&D spends and manufacturing capacity harder and could pressure margins if fixed costs rise without stable revenue expansion.
Declining Assets And Equity Vs Prior YearA shrinking asset base and lower equity versus the prior year can reflect lower cash, asset impairments, or reduced investment capacity. Over months, this may limit the company's ability to fund launches or trials internally and reduces its balance-sheet buffer against execution setbacks.
InnoCare Pharma Ltd. News
INCPF FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was $1.55 and its highest was $3.26 in the past 12 months.
What is InnoCare Pharma Ltd.’s market cap?
InnoCare Pharma Ltd.’s market cap is $2.82B.
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
InnoCare Pharma Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 12 days.
How were InnoCare Pharma Ltd.’s earnings last quarter?
InnoCare Pharma Ltd. released its earnings results on Apr 23, 2026. The company reported $0.009 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is InnoCare Pharma Ltd. overvalued?
According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued.
Does InnoCare Pharma Ltd. pay dividends?
InnoCare Pharma Ltd. does not currently pay dividends.
What is InnoCare Pharma Ltd.’s EPS estimate?
InnoCare Pharma Ltd.’s EPS estimate is 0.01.
How many shares outstanding does InnoCare Pharma Ltd. have?
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
InnoCare Pharma Ltd. reported an EPS of $0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
Currently, no hedge funds are holding shares in INCPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InnoCare Pharma Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.46 (58.44% Upside)
$2.46 (58.44% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
INCPF Stock 12 Month Forecast
Average Price Target
$2.46
▲(58.44% Upside)
Zai Lab Ltd
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Ownership Overview
―
Insiders
3.11% Mutual Funds
― Other Institutional Investors
93.85% Public Companies and
Individual Investors